Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.
about
Long-term course and effectiveness of combination therapy in Alzheimer diseasePlatelet biomarkers in Alzheimer's diseaseA review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's diseaseMagnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis.Current and future uses of neuroimaging for cognitively impaired patients.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease.Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysisMemantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy.Optimum Design of Disease-modifying Trials on Alzheimer's Disease.Donepezil: an update.Present and prospective clinical therapeutic regimens for Alzheimer's disease.Pharmacotherapy of Alzheimer disease.Optimizing parameters in clinical trials with a randomized start or withdrawal designDisease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency.A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis.Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?
P2860
Q24642161-13237817-7AE2-4168-8221-7E56B3142DF2Q26858851-32D853D2-C161-42D5-BA67-03255A2428CEQ27311651-5A6F9484-9B09-4ADC-9DAF-942B7C8C609FQ30996805-B803D7BC-35D4-44CB-BF4C-4B9D808962C5Q31143267-4E93CFE8-B62D-4B2E-AD71-65D8C3CA2C4EQ33165693-8E498290-A36B-4701-B168-DEA48DCAA3DEQ35135672-D2EF0F60-837D-4B3C-8C9A-1B9AA94F56EFQ35620305-798CA029-BD32-46E2-9A68-725EE4AB10D5Q36632693-8975E95C-CA28-4FA4-A98D-B46C842DD42CQ36790787-FD7F4EE3-C342-417D-B13A-B25E5411361CQ36808057-463F95A3-0A32-4B16-8ED2-E1F003EF3801Q36876447-8B9AFD63-8390-4C7C-9076-03A25ADE7FDFQ37004359-B68919A4-F469-44D4-8AB6-05CFFDF9B5ACQ37244770-700CD794-0DBE-4AA4-8BCD-C67731E4173AQ38832928-135BE44C-9049-411F-996A-5B612E2640C5Q39780949-4453D659-26A6-4CB4-9498-11E54F682F27Q46050990-54D766CA-9970-425F-9D68-B5CF7D8ED719Q47161596-3AD624F8-47DC-4B93-9F5D-9A75C341C69D
P2860
Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Challenges to demonstrating di ...... mer's disease clinical trials.
@en
Challenges to demonstrating di ...... mer's disease clinical trials.
@nl
type
label
Challenges to demonstrating di ...... mer's disease clinical trials.
@en
Challenges to demonstrating di ...... mer's disease clinical trials.
@nl
prefLabel
Challenges to demonstrating di ...... mer's disease clinical trials.
@en
Challenges to demonstrating di ...... mer's disease clinical trials.
@nl
P2860
P1476
Challenges to demonstrating di ...... mer's disease clinical trials.
@en
P2860
P304
P356
10.1016/J.JALZ.2006.07.001
P577
2006-10-01T00:00:00Z